Novel Targeted Therapies for Advanced Cholangiocarcinoma
نویسندگان
چکیده
منابع مشابه
Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.
Intrahepatic cholangiocarcinoma (iCCA) is a molecularly heterogeneous hepatobiliary neoplasm with poor prognosis and limited therapeutic options. The incidence of this neoplasm is growing globally. One third of iCCA tumors are amenable to surgical resection, but most cases are diagnosed at advanced stages with chemotherapy as the only established standard of practice. No molecular therapies are...
متن کاملGenetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
Cholangiocarcinoma (CC) encompasses a group of related but distinct malignancies whose lack of a stereotyped genetic signature makes challenging the identification of genomic landscape and the development of effective targeted therapies. Accumulated evidences strongly suggest that the remarkable genetic heterogeneity of CC may be the result of a complex interplay among different causative facto...
متن کاملNovel targeted therapies for mantle cell lymphoma
Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy characterized by short median survival despite intensive therapies. The clinical behavior of MCL may be due to the complex pathophysiology of the disease which includes its genetic hallmark, the chromosomal translocation t(11;14) resulting in aberrant expression of cyclin D1, alteration in the DNA damage response, and constitutive ac...
متن کاملNovel targeted therapies for eosinophilic disorders.
Hypereosinophilic syndromes (HESs) are a diverse group of conditions characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. HESs are chronic disorders with significant morbidity and mortality. Although the availability of targeted chemotherapeutic agents, including imatinib, has improved quality of life and survival in some patients with ...
متن کاملSpecial Issue: Novel targeted therapies
Kazuo Okamoto1,2,3) and Hiroshi Takayanagi *,1,2,3,4) 1)Department of Cell Signaling, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan 2)Global Center of Excellence (GCOE) Program, International Research Center for Molecular Science in Tooth and Bone Diseases, Tokyo, Japan 3)Japan Science and Technology Agency (JST), ERATO, Takayanagi Osteonetwor...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medicina
سال: 2021
ISSN: 1648-9144
DOI: 10.3390/medicina57030212